

ANNOUNCEMENT NO. 228

14 September 2022

Guidance for FY 2022/23

Due to an unfortunate mistake, information regarding ChemoMetec's guidance for FY 2022/23 has today been disclosed to a group of customers in a bank hosting an investor meeting following the publication of ChemoMetec's annual report for FY 2021/22.

ChemoMetec therefore hereby informs that revenue in the range of DKK 485-505m and an operating result (EBITDA) in the range of DKK 245-260m are expected in FY 2022/23. Furthermore, ChemoMetec expects in 2022/23 to invest approx. DKK 70m in product development, patents, production facilities as well as land and buildings etc.

We further inform that ChemoMetec achieved a growth in revenue of 52% in FY 2021/22, where total revenue amounted to DKK 427.2m (2020/21: DKK 281.1m), and that EBITDA was DKK 222.9m (2021/22: DKK 135.6m). This is in line with the most recently disclosed guidance, cf. announcement published on 15 August 2022.

ChemoMetec's annual report for 2021/22 will be published as planned tomorrow, 15 September 2022.

For further information

Steen Søndergaard, CEO, ChemoMetec A/S
Phone: (+45) 4813 1020

About ChemoMetec A/S

ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec's instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec's customers include some of the world's leading pharmaceutical companies, such as Novartis, Novo Nordisk, H. Lundbeck, Merck, AstraZeneca and Johnson & Johnson.

ChemoMetec was founded in 1997 and is listed on the Nasdaq Copenhagen stock exchange. For more information, go to www.chemometec.com